Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs Healthcare Conference. Boula said the meetings “were cordial,” but they were not “digging into the substance yet,” adding that “it is just trying to understand high-level ideas and no commitments. So what could be the outcomes of something like that? It could be from nothing to very big.””
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members
- RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Pfizer (PFE) Faces Tough Choices as Trump Targets U.S. Drug Prices
- Pfizer call volume above normal and directionally bullish